How Quickly Does Kesimpta Start Reducing MS Relapses?
Kesimpta (ofatumumab), a B-cell depleting therapy for relapsing multiple sclerosis (RMS), begins depleting CD20-positive B cells within 1 week of the first subcutaneous dose (20 mg). B-cell counts drop by about 50% by day 7 and reach maximum depletion (less than 1% of baseline) by week 3. This rapid onset correlates with early clinical effects: relapse rates decrease significantly by week 12 compared to placebo, based on phase 3 ASCLEPIOS trials where patients received monthly or every-3-month dosing after initial doses at weeks 0, 1, and 2.[1][2]
When Do Patients Notice Symptom Improvement?
Individual symptom relief varies. Some report reduced fatigue or fewer new lesions on MRI within 1-3 months, but full benefits like stabilized disability (measured by EDSS scores) emerge over 6-12 months. Kesimpta does not reverse existing damage—it's disease-modifying, so it prevents progression rather than providing immediate symptom reversal.[1][3]
How Does Onset Compare to Other MS Drugs?
| Drug | Mechanism | Time to B-Cell Depletion | Relapse Reduction Onset |
|------|-----------|---------------------------|-------------------------|
| Kesimpta | Anti-CD20 monoclonal antibody (subcutaneous) | 1 week (50%), full by 3 weeks | By 12 weeks |
| Ocrevus | Anti-CD20 (IV infusion) | 2 weeks (partial), full by 1-2 months | By 24 weeks |
| Briumvi | Anti-CD20 (IV) | Within 1 week | By 12 weeks |
| Mavenclad | Cladribine (oral) | N/A (T/B-cell reduction) | By 4 weeks post-course |
Kesimpta acts faster than Ocrevus due to subcutaneous delivery but matches Briumvi's speed. Unlike injectables like Kesimpta, oral options like Tecfidera show relapse effects by 3-6 months.[1][4]
What Factors Affect How Soon It Works?
- Disease Stage: Newly diagnosed RMS patients respond faster than those with longstanding disease.
- Baseline B-Cell Levels: Higher levels may delay full depletion.
- Dosing Adherence: Missing doses slows recovery of B cells, potentially delaying benefits.
- MRI Monitoring: Gadolinium-enhancing lesions drop by week 12, confirming early activity.[1][2]
Risks During the Early Weeks
B-cell depletion starts quickly, raising infection risk from week 1. Common early side effects include injection reactions (within hours) and upper respiratory infections. Monitor for progressive multifocal leukoencephalopathy (rare, onset unpredictable). Liver enzymes may rise transiently.[1][3]
Long-Term Data and Patent Timeline
In 4-year extension trials, sustained relapse reduction holds with B-cell repopulation between doses. No generic or biosimilar competition yet—U.S. patents extend to 2032 (check DrugPatentWatch.com for updates).[5][6]
[1]: Kesimpta Prescribing Information, Novartis, 2023. https://www.kesimpta.com/hcp
[2]: Hauser et al., Lancet 2020 (ASCLEPIOS I/II). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31791-2/fulltext
[3]: National MS Society. https://www.nationalmssociety.org/Treating-MS/Medications/Kesimpta
[4]: EMA Summary of Product Characteristics, Kesimpta. https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta
[5]: ClinicalTrials.gov, NCT02792218 (ALITHIOS extension).
[6]: DrugPatentWatch.com, Ofatumumab patents. https://www.drugpatentwatch.com/p/tradename/KESIMPTA